-
EU Slaps Tariffs on Chinese EVs | Business Matters (Oct. 30) -
The Market Might As Well Close Every August
-
JP Morgan: Recession Now More Likely; Average American Now Carrying Over $6,300 in Credit Card Debt | Business Matters Full Broadcast (Aug. 8)
-
Eli Lilly to Sell Weight Loss Drugs Directly to Patients
-
Eli Lilly Launches Digital Health Care Platform to Help Patients With Chronic Disease
-
Novo Nordisk Sues 2 Pharmacies for Allegedly Selling Adulterated Weight-Loss Drugs
-
Safety Concerns Loom as Obesity Drugs Head to Clinical Trials in Kids as Young as 6
-
Eli Lilly Sues Clinics Over Alleged Sales of Unapproved Versions of Diabetes Drug
-
Top 5 US Pharma Companies Netted $82 Billion in 2022: Report
-
UK Public Agency Won’t Recommend Weight Loss Drug Mounjaro, Needs More Evidence
-
Sen. Sanders Asks Insulin Manufacturers to Testify Before Senate HELP Panel
-
Major Drugmaker to Cut Insulin Prices for Americans
-
FDA Pulls Authorization for Eli Lilly’s COVID-19 Drug Bebtelovimab
-
Alzheimer’s Drug Breakthrough Big Boost for Roche, Eli Lilly
-
Eli Lilly Sued for Age Discrimination by US Agency EEOC
-
Major Drug Company Announces Change Over Indiana’s Abortion Ban
-
FDA Rejects Eli Lilly’s China-Developed Cancer Drug
-
FDA Restricts Use of 2 Monoclonal Antibody Treatments
-
Judge Hears Opening Arguments on Biden Administration’s Alleged Purge of Industry From EPA Panels
-
Lab Tests: Eli Lilly, Regeneron Antibody Therapies Lose out Against Omicron
-
FDA Authorizes Eli Lilly’s COVID-19 Antibody Therapy for Children
-
FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization
-
FDA Gives Eli Lilly’s Experimental COVID-19 Antibody Drug Emergency Clearance
-
Antibody Treatment Shows Improvement in Patients With Mild to Moderate Infection
-
NIH Announces Halt to Eli Lilly Antibody Treatment on Hospitalized COVID-19 Patients
-
Eli Lilly Pauses COVID-19 Drug Trial Due to Safety Concerns
-
Drugmaker Eli Lilly Caps Insulin Costs at $35 as CCP Virus Crisis Deepens
